Bone and joint involvement in fabry disease

Scandinavian Journal of Rheumatology

Volumn 39, Issue 2, 2010, Pages 171-174

  Sacre, K ^a   Lidove, O ^a   Leprieur, B Giroux ^a   Ouali, N ^b   Laganier, J ^a   Caillaud, C ^c   Papo, T ^a  

^a BICHAT HOSPITAL   (France)

^b HÔPITAL TENON   (France)

^c University Paris 5 ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; METHYLPREDNISOLONE; VITAMIN D;

ABDOMINAL PAIN; ADULT; ANHIDROSIS; ARTHROPATHY; ARTICLE; BONE DEMINERALIZATION; BONE DENSITY; BONE NECROSIS; CALCANEUS FRACTURE; CASE REPORT; DRUG HYPERSENSITIVITY; DUAL ENERGY X RAY ABSORPTIOMETRY; EDEMA; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; FRAGILITY FRACTURE; HEMANGIOKERATOMA; HUMAN; MALE; MISSENSE MUTATION; OSTEOPOROSIS; PARESTHESIA; PHYLOGENY; PRIORITY JOURNAL; SOFT TISSUE DISEASE; SUBLUXATION; TELANGIECTASIA;

ABSORPTIOMETRY, PHOTON; ADULT; BONE DISEASES, METABOLIC; DISEASE PROGRESSION; FABRY DISEASE; FEMALE; FRACTURES, BONE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OSTEOPOROSIS; PEDIGREE; SEVERITY OF ILLNESS INDEX; SIBLINGS; TREATMENT OUTCOME;

EID: 77950271972     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009740903270631     Document Type: Article

References (12)

1. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967;276:1163-1167
2. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, et al. Fabry disease, an under-recognizedmultisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003;138:338-346
3. Germain DP, Benistan K, Boutouyrie P, Mutschler C. Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease. Clin Genet 2005;68:93-95
4. Mersebach H, Johansson JO, Rasmussen AK, Bengtsson BA, Rosenberg K, Hasholt L, et al. Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density. Genet Med 2007;9:812-818
5. Banikazemi M, Ullman T, Desnick RJ. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab 2005;85:255-259
6. Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med 2008;358:1474-1482
7. Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, El-Hajj Fuleihan G. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002;58:1348-1353
8. Pastores GM, Wallenstein S, Desnick RJ, Luckey MM. Bone density in Type 1 Gaucher disease. J Bone Miner Res 1996;11: 1801-1807
9. Horiuchi H, Saito N, Kobayashi S, Ota H, Taketomi T, Takaoka K. Avascular necrosis of the femoral head in a patient with Fabry's disease: identification of ceramide trihexoside in the bone by delayed-extraction matrix-assisted laser desorption ionizationtime- of-flight mass spectrometry. Arthritis Rheum 2002;46: 1922-1925
10. Brower AC, Allman RM. Pathogenesis of the neurotrophic joint: neurotraumatic vs. neurovascular. Radiology 1981;139: 349-354
11. Kaye EM,Kolodny EH, Logigian EL, Ullman MD. Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation. Ann Neurol 1988;23:505-509
12. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alphagalactosidase A - replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16.